drugset / Trial / NCT00604708

Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

NCT00604708

Phase 3 Completed 867 enrolled Valneva Austria GmbH
RandomizedParallel-groupSingle-blindPrevention

Summary

The objective is to demonstrate the non-inferiority of the Japanese Encephalitis vaccine IC51 compared to JE-VAX in healthy subjects aged \> or = 18 years

Timeline

Start
2005-09
Primary completion
2006-09
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject IC51 Vaccine 6 ug Intramuscular
Comparator JE-VAX® Vaccine 1 ml Subcutaneous

Indications